Evotec SE Stock (DE0005664809): Insider Sale by CSO Cord Dohrmann Draws Attention

Evotec SE shares came under pressure on June 16 as a major management board member, Chief Scientific Officer Dr. Cord Dohrmann, reported a sizable share sale. The insider transaction adds a new angle for investors tracking the MDAX-listed biotech stock.

Responsible: ad hoc news Insider & Companies Desk. Reviewed prior to publication on June 16, 2026 at 8:22 PM ET. Details in the imprint.

Evotec SE is back in focus on Tuesday after a fresh insider filing revealed that Chief Scientific Officer Dr. Cord Dohrmann has sold a substantial block of shares, while the stock traded lower in the German mid-cap index MDAX.

Insider sale by CSO Cord Dohrmann reported

According to an EQS notification disseminated on June 16, 2026 and reported by MarketScreener, Evotec CSO and management board member Dr. Cord Dohrmann executed a sale of shares in Evotec SE, classified as a transaction by a person discharging managerial responsibilities.

The EQS filing lists the instrument as Evotec SE shares with the ISIN DE0005664809 and specifies a transaction type of "Verkauf" (sale), confirming that the trade reduced Dohrmann's direct exposure rather than reflecting an option exercise or grant.

In the notification, the reported transaction price is indicated at 4.81 EUR per share for an overall volume of 576,720.00 EUR, implying a sale of approximately 120,000 Evotec shares by the long-serving research executive.

The transaction was formally published via EQS at around 5:45 PM CET on June 16, 2026, with Evotec SE named as the responsible issuer and contact details pointing to the company's Hamburg headquarters and corporate website.

EQS characterizes the disclosure as a notification and public announcement of dealings by a person fulfilling managerial responsibilities, underscoring that the sale falls under the European Market Abuse Regulation regime for directors' dealings.

For investors tracking governance and alignment between management and shareholders, director dealings of this scale tend to be monitored closely, especially when they involve members who are tightly linked to the scientific and strategic core of a biotech platform.

Share price under pressure on the same day

While the insider sale was being disclosed, Evotec's share price moved lower in Tuesday trading on Xetra, putting the stock on the losers' side of the MDAX.

Data from finanzen.ch show that around 12:28 PM CET on June 16, 2026, Evotec SE shares traded down about 1.1 percent at 4.83 EUR on Xetra, with the stock "in red" and listed among the intraday decliners in the index.

A later snapshot from aktiencheck.de indicated that Evotec's Xetra closing quote was 4.728 EUR, down from a prior close of 4.896 EUR, equivalent to a decline of roughly 3.43 percent for the session on June 16, 2026.

That negative move contrasts with a recent level around 5.175 EUR recorded at Xetra on May 22, 2026 at 10:51 AM, when the stock was up about 1.87 percent on the day according to comdirect, highlighting that the shares have retraced from that late-May quotation.

The same aktiencheck.de data table lists Evotec's 52-week high and low in a corridor between 7.85 EUR and 4.00 EUR, framing the current price regionally in the lower half of this one-year trading range.

In Tuesday's midday session, finanzen.ch notes that the MDAX itself was quoted at roughly 32,734 points, with Evotec's stock standing on the negative side of the index's internal leaderboard at that time.

Real-time Xetra order book information compiled by FinanzNachrichten suggests that, in recent sessions, Evotec has typically traded near the 5.170 EUR mark with regular liquidity in the order book, although the exact intraday levels vary with broader market conditions and stock-specific news.

From a US retail investor's perspective, Evotec remains primarily a Germany-listed biotech name and does not feature in major US equity benchmarks such as the S&P 500, Dow Jones Industrial Average or Nasdaq Composite, which can limit its visibility on US-centric trading platforms.

However, the MDAX membership underlines that Evotec still occupies a notable position within the German mid-cap universe, with its share price sometimes serving as a sentiment gauge for European life-science and drug-discovery names rather than for the large-cap US biotech cohort.

Company profile and strategic backdrop

Evotec describes itself as a life-science company focused on discovering and developing small molecules, biologics, cell therapies and related modalities, with its platforms powered by molecular patient databases, PanOmics technologies and induced pluripotent stem cell (iPSC)-based disease models.

The company positions these capabilities as an integrated drug-discovery and development engine that it deploys through partnerships with large pharmaceutical, biotechnology and academic institutions, targeting a portfolio of collaborative and proprietary pipeline programs.

Evotec's corporate head office is located at the Manfred Eigen Campus, Essener Bogen 7 in 22419 Hamburg, Germany, with contact details including a Hamburg telephone number and the corporate website, confirming its role as a Germany-based but globally oriented research and development platform.

In earlier news flow, aktiencheck.de pointed out that Evotec stands to receive about 100 million US dollars from the sale of its stake in Tubulis, a company that is being acquired by Gilead Sciences, adding a capital markets angle to Evotec's broader partnership strategy and asset monetization efforts.

While that Tubulis-related cash inflow reflects optionality embedded in Evotec's portfolio of partnered programs and equity stakes, the timing and precise use of proceeds at the Evotec corporate level will be shaped by future management decisions and capital allocation priorities.

The interplay between Evotec's collaboration-driven business model, its investment in enabling platforms such as PanOmics and iPSC technologies, and the cyclicality of biotech funding markets can influence how investors weigh individual news items like insider sales or pipeline milestones.

Insider activity in context

Director dealings notifications like the one involving Dr. Dohrmann are common across European listed companies and are not unusual within the biotech sector, where senior executives often hold equity stakes accumulated through long-term incentives, participation in share programs or earlier career phases.

In regulatory terms, such transactions must be reported to the market once specified thresholds are met, and the EQS format used in the Evotec case follows the standardized template for market abuse regulation disclosures across German issuers.

It is important to note that an insider sale can have many possible motivations, ranging from portfolio diversification to personal liquidity needs, tax planning or timing around vesting events, and it does not automatically signal a change in the executive's assessment of the company's long-term prospects.

Nonetheless, because Dr. Dohrmann is strongly associated with Evotec's research strategy and pipeline steering, market participants often consider the scale and frequency of his trades alongside other indicators, such as R&D news flow, partnership announcements or changes in guidance.

The latest EQS entry adds another data point to the director dealings history for Evotec and will likely be cataloged by governance-focused data providers and institutional investors who systematically track insider trading patterns at European mid-cap companies.

Market reaction and investor takeaway

The same-day combination of a director dealing disclosure and a visible share price decline naturally raises the question whether the insider sale contributed to the market move, or whether both developments simply coincided within an already volatile trading environment for European biotech stocks.

On the one hand, the absolute trading size in the reported transaction, at roughly 576,720 EUR, is meaningful but not overwhelming relative to Evotec's typical Xetra trading volumes, which often run into hundreds of thousands of shares per day according to order book snapshots.

On the other hand, sentiment in the broader life-science sector has been choppy in recent quarters, and MDAX constituents in cyclically sensitive or research-intensive fields can face amplified price swings when risk appetite wavers or when investors rebalance toward more defensive large caps.

In summary, the new insider sale by Evotec CSO Cord Dohrmann adds a governance and sentiment angle to a stock that was already trading closer to the lower end of its 52-week range, and investors watching the stock may factor this disclosure into their broader assessment of Evotec's risk-reward profile.

Key facts on the Evotec SE stock

• Name: Evotec SE
• Industry: Life-science and drug discovery platforms
• Headquarters: Hamburg, Germany
• Core markets: Global pharmaceutical, biotech and academic research partners
• Revenue drivers: Drug discovery collaborations, development milestones, licensing and partnered pipelines
• Listing: Xetra/Frankfurt (MDAX constituent), ISIN DE0005664809, German ticker EVT
• Trading currency: Euro (EUR)

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.